Myriad Loses Appeals Court Bid to Block Breast Cancer Tests

by jeeg 18. December 2014 00:54
  Myriad Genetics Inc. can’t block competitors’ DNA tests to determine risk for breast and ovarian cancer after a U.S. appeals court said three patents on the tests never should have been issued. The patents cover products of nature and ideas that aren’t eligible for legal... [More]
Log in